Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06445699
Other study ID # RYin
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2023
Est. completion date June 2024

Study information

Verified date June 2024
Source Army Medical University, China
Contact Rui Yin, MD, PhD
Phone 13101201667
Email swyinrui@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

63 patients with chronic infectious wounds were enrolled in the controlled study. They were randomly divided into three groups equally. Group 1 (Grp.1): The patients received hydrogel dressing change at three days intervals. Group 2 (Grp.2): The patients received ALA-PDT treatment at ten days intervals for 4 sessions. Groups 3 (Grp.3): The patients received ALA-PDT at ten days intervals for 4 sessions combined with hydrogel dressing change every three days intervals. The wound healing rate, total effective rate, patient satisfaction, adverse reaction, and recurrence were assessed in all groups.


Description:

Randomly divide the enrolled patients into three groups for treatment by utilizing SAS software (SAS Institute, Cary, NC, U.S.A.). Initially, the wound pus and secretions were washed three times with a sterile saline solution. Subsequently, surgical instruments were employed to debride the wound, particularly the necrotic tissue, as well as any carrion and foreign bodies within the wound bed and cavity, with care being taken to avoid injury to nerves and blood vessels in the surrounding area. Grp.1 was covered with hydrogel dressing (PAUL HARTMANN AG, Germany) and replaced 2-3 times a week with topical mupirocin ointment three times a day. Grp.2 received photodynamic therapy only. Grp.3 accepted PDT, then coated with hydrogel dressing as mentioned above. The treatment protocol of PDT is described as follows: after thorough debridement, ALA (Shanghai Fudan-Zhang jiang Bio-Pharmaceutical Co. Ltd, China) in an oil-in-water emulsion was smeared on the wound. After covering with dark plastic film for 3h, the wounds were illuminated by a light-emitting diode (LED) red light (Shenzhen Lifotronic Technology Co., Ltd, China). After the operation, a cold ice compress can be used to relieve the swelling and pain. Then, the hydrogel was uniformly applied to the wound and its surroundings (Grp.3). Grp.2 and Grp.3 received PDT at an interval of ten days for 4 sessions. In all groups, treatment responses and adverse reactions were recorded. All patients received the treatment as mentioned above and then evaluated the clinical outcome. After the end of the treatment, all patients returned for follow up at weeks 2, 4, 8 and 12.


Recruitment information / eligibility

Status Recruiting
Enrollment 69
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - 1) patients with chronic wounds caused by trauma or surgery who failed to heal after traditional formal medical treatment at least over three months; - 2) Patients with stable vital signs who had no systemic medical disease and did not take glucocorticoids, immunosuppressive agents, or anticoagulants during the entire treatment process; - 3) Participants provided signed informed consent, were able to comply with the program, were willing to participate in follow-up, and were able to cooperate in the observation of adverse events and efficacy; - 4) The diameter of the skin wound should not exceed 10 centimeters. Exclusion Criteria: - 1) Patients are allergic to ALA; - 2) Women with recent fertility, pregnancy or lactation plans; - 3) Patients with deepening wounds or worsening infections; - 4) Poor compliance leading to an inability to complete the treatment in its entirety; - 5) Cutaneous ulcer caused by vascular disease, autoimmune diseases, metabolic diseases, local or metastatic malignant tumors.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Photodynamic therapy
A number of studies have reported that PDT can accelerate wound healing by inactivating local bacterial infection and colonization of bacterial biofilm, promoting wound re-epithelialization.
Hydrogel dressing
Hydrogel dressing is widely applied in clinical practice to improve the regeneration ability of wound granulation tissue, promote the division and migration of epithelial cells, speed up wound healing and relieve the pain.

Locations

Country Name City State
China Department of Dermatology, Southwest Hospital, Third Military Medical University (Army Medical University) Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Army Medical University, China

Country where clinical trial is conducted

China, 

References & Publications (5)

Khorsandi K, Hosseinzadeh R, Esfahani H, Zandsalimi K, Shahidi FK, Abrahamse H. Accelerating skin regeneration and wound healing by controlled ROS from photodynamic treatment. Inflamm Regen. 2022 Oct 4;42(1):40. doi: 10.1186/s41232-022-00226-6. — View Citation

Morley S, Griffiths J, Philips G, Moseley H, O'Grady C, Mellish K, Lankester CL, Faris B, Young RJ, Brown SB, Rhodes LE. Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobial therapy. Br J Dermatol. 2013 Mar;168(3):617-24. doi: 10.1111/bjd.12098. Epub 2013 Jan 18. — View Citation

Nesi-Reis V, Lera-Nonose DSSL, Oyama J, Silva-Lalucci MPP, Demarchi IG, Aristides SMA, Teixeira JJV, Silveira TGV, Lonardoni MVC. Contribution of photodynamic therapy in wound healing: A systematic review. Photodiagnosis Photodyn Ther. 2018 Mar;21:294-305. doi: 10.1016/j.pdpdt.2017.12.015. Epub 2017 Dec 28. — View Citation

Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020 Jul;21(7):363-383. doi: 10.1038/s41580-020-0230-3. Epub 2020 Mar 30. — View Citation

Xu Y, Chen H, Fang Y, Wu J. Hydrogel Combined with Phototherapy in Wound Healing. Adv Healthc Mater. 2022 Aug;11(16):e2200494. doi: 10.1002/adhm.202200494. Epub 2022 Jul 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Adverse effects The severity (absent; mild; moderate; severe) and duration of adverse reactions such as pain, burning sensation, erythema, oedema and pigmentation, treatment measures and efficacy were meticulously documented at each treatment and follow-up. Up to 12 weeks after the end of the treatment.
Other Recurrence Patients were surveyed about the recurrence after 12 weeks following the final course of treatment. Up to 12 weeks after the end of the treatment.
Primary Wound healing rate Panoramic photographs of the wounds were taken by the same observer at each treatment and return visit using a digital camera, and the wound area was recorded using Image-Pro Plus 6.0 software. Wound size on the first day of treatment was considered to be 100%. The change in wound area size was compared to the initial before treatment and calculated as a percentage reduction. Up to 12 weeks after the end of the treatment.
Primary The total effectiveness rate The evaluation criteria were as follows: 1) If the wound area is completely healed, treatment was considered "significantly effective" (SE); 2) if the wound area was at least 50% healed, treatment was considered "effective" (E); 3) If the wound area was healed 30 - 50%, the treatment is considered as "improved" (IMP); 4) If the wound area is healed less than 30%, it is considered as "ineffective" (INE). "The total effectiveness rate" (Et) was calculated from the equation as follows:
Et = (NSE+NE)/Nt × 100% NSE = the number of patients belonging to the SE groups NE = the number of patients belonging to the E groups Nt = the total number of patients
Up to 12 weeks after the end of the treatment.
Primary Patient satisfaction Patients were surveyed about their level of satisfaction with the results after 12 weeks following the final course of treatment with the results as "satisfied," "somewhat satisfied," "somewhat dissatisfied," or "dissatisfied." Up to 12 weeks after the end of the treatment.
See also
  Status Clinical Trial Phase
Recruiting NCT06052033 - Comparison of 5-ALA Photodynamic Therapy and CO2 Laser for Treating Persistent Low-Grade Cervical Lesions With High-Risk HPV Infection N/A
Recruiting NCT05031923 - Treatment of Intrabony Defects With Simvastatin and Antimicrobial Photodynamic Therapy N/A
Completed NCT04037709 - Photodynamic Therapy in Patients With Gingivitis N/A
Recruiting NCT05043935 - The Effect of Leukocyte and Platelet-rich Fibrin With Antimicrobial Photodynamic Therapy in Aggressive Periodontitis N/A
Not yet recruiting NCT06437288 - Hematoporphyrin Photodynamic Therapy for Esophageal Cancer Phase 2
Completed NCT01756313 - Optimizing Uptake of Methylaminolevulinat With Fractional Ablative Laser Technique Phase 4
Withdrawn NCT03960125 - Photodynamic Therapy and Microvesicles Early Phase 1
Recruiting NCT01349361 - Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Phase 2
Not yet recruiting NCT06468540 - Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Recruiting NCT05688904 - The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy Phase 1
Completed NCT04037475 - Treatment of Herpes Labialis by Photodynamic Therapy N/A
Recruiting NCT04689243 - Low Concentration ALA-PDT in Treatment of Skin Ulcer N/A
Recruiting NCT06311890 - Study to Evaluate the Efficacy, Safety and Tolerability of Photodynamic Therapy(PDT) With Chlorin-e6 in Treating Moderate to Severe Acne Phase 2
Enrolling by invitation NCT05820750 - Clinical and Radiographic Evaluation of Photodynamic Therapy for Root Canal Treatment of Primary Molars N/A
Enrolling by invitation NCT04223570 - Portable Measurement of Protoporphyrin IX in the Skin
Completed NCT03643744 - Photodynamic Therapy-Induced Immune Modulation: Part III Phase 1